About AlcHepNet

The Alcohol-associated Hepatitis Network project, AlcHepNet, comprised of ten leading partner institutions in the field, will collect and organize patient information, associated data, and samples that can help shed greater light on this disease. Combined, these approaches will improve treatment and how we care for patients with this devastating liver condition.

Alcohol-associated hepatitis (AH) is a leading cause of liver-related morbidity and mortality. This network represents a coordinated submission of several NIAAA-funded consortia that have come together as the Alcohol-associated Hepatitis Network (AlcHepNet). Collectively, the network will synergize efforts and expertise to better understand AH. The network aims to:

Develop a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD).

The primary purpose study is to determine whether subjects receiving AUD treatments combined with sAH therapies will improve alcohol and liver-related events at 6 months compared to usual care for AUD. Patients will receive either integrated treatment with acamprosate and counseling or standard care with brief advice and referral to a 12-step program.

The secondary purpose of the study is to determine if F-652 is safe and effective in treating severe alcohol-associated hepatitis when compared to prednisone. Subjects will receive F-652 on days 1 and 7 or prednisone for 28 days. Outcomes will be measured by overall survival at 90 days.

AlcHepNet Organizations